Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Menlo Therapeutics Inc. (FOMX) (FOMX)

2.99   0 (0%) 03-06 16:00
Open: 3.18 Pre. Close: 2.99
High: 3.438 Low: 2.9
Volume: 1,517,628 Market Cap: 183M
Foamix Pharmaceuticals Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in developing and commercializing minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. Its products include FMX101 & FMX103.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.997 - 3.017 3.017 - 3.035
Low: 2.94 - 2.966 2.966 - 2.989
Close: 2.951 - 2.991 2.991 - 3.027

Technical analysis

as of: 2020-04-09 4:30:36 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.68     One year: 5.48
Support: Support1: 2.90    Support2: 2.41
Resistance: Resistance1: 4.01    Resistance2: 4.69
Pivot: 3.67
Moving Average: MA(5): 3.17     MA(20): 3.87
MA(100): 3.59     MA(250): 3.22
MACD: MACD(12,26): -0.27     Signal(9): -0.15
Stochastic oscillator: %K(14,3): 6.65     %D(3): 9.34
RSI: RSI(14): 25.85
52-week: High: 4.84  Low: 1.97  Change(%): -27.6
Average Vol(K): 3-Month: 56566  10-Days: 66294

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
FOMX has closed above bottom band by 12.8%. Bollinger Bands are 65.5% wider than normal. The large width of the bands suggest high volatility as compared to FOMX's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue.

Headline News

Mon, 09 Mar 2020
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications - GlobeNewswire

Mon, 11 Nov 2019
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications - GlobeNewswire

Fri, 17 Jan 2020
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics - GlobeNewswire

Thu, 06 Feb 2020
Foamix and Menlo Announce Shareholder Approval of Proposed Merger - GlobeNewswire

Thu, 06 Feb 2020
Foamix (FOMX), Menlo Therapeutics (MNLO) Shareholders Approve Merger - StreetInsider.com

Mon, 18 May 2020
May 18, 2020 - Perceptive Advisors Llc Buys Iovance Biotherapeutics Inc, Zymeworks Inc, Regeneron Pharmaceuticals Inc, Sells Amarin Corp PLC, Momenta Pharmaceuticals Inc, Foamix Pharmaceuticals - GuruFocus.com

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange: 
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 61
Shares Float (M) 46
% Held by Insiders 1.56
% Held by Institutions 49.99
Shares Short (K) 3,330
Shares Short P. Month (K) 3,130

Stock Financials

EPS -1.310
EPS Est This Year -1.530
EPS Est Next Year -1.520
Book Value (p.s.) 0.880
Profit Margin
Operating Margin -6270.63
Return on Assets (ttm) -46.5
Return on Equity (ttm) -90.1
Qtrly Rev. Growth
Gross Profit (p.s.) 0.059
Sales Per Share 0.019
EBITDA (p.s.) -1.190
Qtrly Earnings Growth
Operating Cash Flow (M) -62
Levered Free Cash Flow (M) -37

Stock Valuations

PE Ratio -2.28
PEG Ratio
Price to Book value 3.40
Price to Sales
Price to Cash Flow -2.95

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.